TSBX vs. AVRO, IKNA, LENZ, ENTX, GNTA, CDTX, ATRA, CRIS, CVM, and INAB
Should you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include AVROBIO (AVRO), Ikena Oncology (IKNA), LENZ Therapeutics (LENZ), Entera Bio (ENTX), Genenta Science (GNTA), Cidara Therapeutics (CDTX), Atara Biotherapeutics (ATRA), Curis (CRIS), CEL-SCI (CVM), and IN8bio (INAB). These companies are all part of the "medical" sector.
Turnstone Biologics (NASDAQ:TSBX) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.
Turnstone Biologics presently has a consensus price target of $19.00, suggesting a potential upside of 562.02%. AVROBIO has a consensus price target of $2.00, suggesting a potential upside of 43.88%. Given Turnstone Biologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Turnstone Biologics is more favorable than AVROBIO.
In the previous week, AVROBIO had 5 more articles in the media than Turnstone Biologics. MarketBeat recorded 7 mentions for AVROBIO and 2 mentions for Turnstone Biologics. AVROBIO's average media sentiment score of 1.13 beat Turnstone Biologics' score of -1.50 indicating that AVROBIO is being referred to more favorably in the news media.
52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 62.6% of AVROBIO shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by insiders. Comparatively, 9.2% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
AVROBIO has lower revenue, but higher earnings than Turnstone Biologics.
AVROBIO's return on equity of -50.52% beat Turnstone Biologics' return on equity.
AVROBIO received 170 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 66.93% of users gave AVROBIO an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote.
Summary
AVROBIO beats Turnstone Biologics on 8 of the 13 factors compared between the two stocks.
Get Turnstone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Turnstone Biologics Competitors List
Related Companies and Tools
